Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors
Alison M. Schram(Memorial Sloan Kettering Cancer Center), Jayesh Desai(Peter MacCallum Cancer Centre), Jia‐Rong Chen(Central China Normal University), Rasha Cosman(UNSW Sydney), Mark P. Johnson(California University of Pennsylvania), Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Badreddin Edris(Stanford Medicine), Eric Sbar(Pfizer (United States)), Vincent Amoruccio, Thuy Hoang, Adeela Kamal, Jia Liu(The University of Sydney), Lusong Luo(Beijing Biocytogen (China)), Todd Shearer, Wenlin Shao, Jocelyn Lewis, Ryan J. Sullivan(Dana-Farber Cancer Institute)
Cited by 12
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.2k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
A Randomized Trial of Prenatal versus Postnatal Repair of Myelomeningocele
|New England Journal of Medicine|2011|2.2k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k